Market capitalization | $5.66b |
Enterprise Value | $5.64b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 15.53 |
P/S ratio (TTM) P/S ratio | 15.60 |
P/B ratio (TTM) P/B ratio | 17.62 |
Revenue growth (TTM) Revenue growth | 60.80% |
Revenue (TTM) Revenue | $362.80m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
19 Analysts have issued a Blueprint Medicines Corp. forecast:
19 Analysts have issued a Blueprint Medicines Corp. forecast:
Jun '24 | |
Current assets | 904 904 |
Fixed assets | 300 300 |
Total Assets | 1,204 1,204 |
Jun '24 | |
Equity | 320 320 |
Debt capital | 883 883 |
Total Capital | 1,204 1,204 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Kathryn Haviland |
Employees | 655 |
Founded | 2008 |
Website | www.blueprintmedicines.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.